Cg Oncology, Inc. · NASDAQ:CGON

Cg Oncology — Technical Presentation (September 2025)

14 slides from Cg Oncology's technical presentation, Sep 6, 2025

  1. Slide 1: Encore Durability Results From BOND-003 Cohort C

    Encore Durability Results From BOND-003 For individual reference only. The information accessed through this QR code is Cohort C: Single-Arm Study of Intravesical intended solely for individual reference and should not be altered, modified, or reproduced in any way. Cretostimogene Grenadenorepvec fo

  2. Slide 2: Disclosures

    Disclosures ‣ Grants: NIH SBIR, DOD, AUA Care Foundation (mentor). ‣ Clinical trials: CG Oncology, Ferring Pharmaceuticals. ‣ Scientific Advisory Board: UroGen, CG Oncology, Pfizer. ‣ Co-Founder: OncoSTING LLC (www.OncoSTING.com). 2

  3. Slide 3: Cretostimogene Selectively Targets Rb-E2F Pathway Altered Cancers

    Cretostimogene Grenadenorepvec Selectively Targets Rb-E2F Pathway Altered Cancers ‣ Conditionally replicating, highly immunogenic adenovirus o Under regulation of the human E2F-1 promoter - Selective for RB-E2F pathway alterations o Encodes GM-CSF transgene ‣ Oncolytic immunotherapy with dual MOA o

  4. Slide 4: Phase 3 Cretostimogene Monotherapy for High-Risk BCG-Unresponsive NMIBC with CIS

    Phase 3 Cretostimogene Monotherapy for High-Risk BCG-Unresponsive NMIBC with CIS HR BCG-Unresponsive NMIBC Cretostimogene Grenadenorepvec Primary Endpoint: Single-Arm, Open-Label, IVE Administration CR at Any Time Population Study Design / Regimen Additional Endpoints ‣ Enrollment complete (n=112) ‣

  5. Slide 5: Patient Demographics & Baseline Characteristics

    Patient Demographics & Baseline Characteristics Subjects in Safety Dataset N=112 % Gender Male 83 74.1 Female 29 25.9 Age (Years) ‣ Majority of patients are:Legend Mean (SD) 72.9 (9.19) 74.0 (43-90) o Male (74%) Median (Range) Age (Categories) o White (62%) < 65 19 17.0 o > 65 years (83%) ≥ 65 and <

  6. Slide 6: Consistent and Compelling CR & 24-Month Durability Data

    Consistent and Compelling CR & 24-Month Durability Data Overall Complete Response CR CR Rate, % CR by K-M Est, % 75.5% 100 Landmark (95% CI) (95% CI) (95% CI, 66.3 % - 83.2 %) Legend 12-month 46.4% (36.9, 56.1) 50.7% (40.9, 59.8) 75 51 out of 110 patients Overall CR Rate (%) 41.8% (32.5, 51.6) 24-mo

  7. Slide 7: Cretostimogene Demonstrates Best in Class Duration of Response

    Cretostimogene Demonstrates Best in Class Duration of Response in HR BCG-UR NMIBC Estimated DOR Probability at 12 Months Duration of Response Probability (%) Estimated DOR Probability 64.1% at 24 Months (95% CI: 52.4-73.7) 58.3% (95% CI: 46.3-68.5) ‣ Median DoR is 27.9 months and ongoing (95% CI 14.

  8. Slide 8: Sustained Responses Observed Over 45 Months

    Sustained Responses Observed Over 45 Months ‣ 50.0% of patients reinduced with oncolytic immunotherapy converted to CR o 64.3% remain in durable response after conversion to CR ‣ Patients remain in response after treatment completion Efficacy data cutoff as of 14MAR2025. 1 Per 2018 FDA Guidance Docu

  9. Slide 9: High CR Rate Consistent Across Patient Subgroups

    High CR Rate Consistent Across Patient Subgroups, Including Patients Treated with Prior Chemotherapy Complete Response Rate (95% CI) 9

  10. Slide 10: Favorable and Well-Tolerated Safety Profile

    Favorable and Well-Tolerated Safety Profile Cretostimogene (n=112) Preferred Term (MedDRA v.26.1) Any Grade (%) Grade ≥ 3 ‣ Most AEs were Grade 1-2 0 (0) ‣ 0% Grade ≥ 3 TRAEs or deaths Patients with ≥ 1 TRAE 71 (63.4%) ‣ Median time to TRAE resolution: 1 day Treatment-Related AE reported in > 10% pa

  11. Slide 11: Viral Replication and Transgene Expression

    Viral Replication and Transgene Expression Pre-Dose Creto Titer Pre-Dose GM-CSF ‣ Cretostimogene replication and 1000 Post-Dose Creto Titer Post-Dose GM-CSF 108 GM-CSF expression are linked 107 ‣ Urine levels peak immediately after instillation and are locally Cretostimogene Titer in Urine (Genome C

  12. Slide 12: Key Takeaways

    Key Takeaways ‣ Highly effective and very well-tolerated regimen ‣ Best in class durability and tolerability ‣ Robust and stable anti-tumor response ‣ Heavily pre-treated BCG-UR CIS containing cohort ‣ Scalable within existing clinic workflow; administered by MAs & RNs ‣ Future and ongoing clinical

  13. Slide 13: First Results: BOND-003 Cohort P HR NMIBC BCG-Unresponsive HG Ta/T1

    First Results: BOND-003 Cohort P HR NMIBC BCG- Unresponsive HG Ta/T1 Kaplan-Meier Estimate for High Grade Recurrence-Free Survival ‣ Data from first 24 treated patients ‣ Strong early responses with HG Recurrence-Free Survival (%) 90.5% HG-RFS (95% CI: 77.9-100%) at 3 and 9 Months ‣ Very well-tolera

  14. Slide 14: Thank You

    Thank You All Bladder Cancer Patients and Their Families Key Investigators, Study Coordinators, Nurses Key Collaborators CG Oncology For individual reference only. The information accessed through this QR code is intended solely for individual Gary Steinberg, Rush University, IL Andy Darilek referen

CG Oncology — Technical Presentation (September 2025) on 6ix